Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Anacor Pharmaceuticals, Inc. | a16-1587_1ex99d1.htm |
EX-99.2 - EX-99.2 - Anacor Pharmaceuticals, Inc. | a16-1587_1ex99d2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 7, 2016
Anacor Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
001-34973 |
|
25-1854385 |
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
1020 East Meadow Circle
Palo Alto, CA 94303-4230
(Address of Principal Executive Offices and Zip Code)
Registrants telephone number, including area code: (650) 543-7500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
Anacor Pharmaceuticals, Inc. (the Company) will be conducting investor meetings during the week of January 11, 2016. A copy of the investor presentation that may be used by representatives of the Company at such meetings is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished to the Securities and Exchange Commission and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On January 7, 2016, the Company issued a press release announcing its submission to the U.S. Food and Drug Administration of a New Drug Application seeking approval of crisaborole topical ointment, 2% for the treatment of mild-to-moderate atopic dermatitis. A copy of such press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
|
Description |
99.1 |
|
Investor Presentation |
99.2 |
|
Press Release issued January 7, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ANACOR PHARMACEUTICALS, INC. | ||
|
|
| |
|
By: |
/s/ Graeme Bell | |
|
|
Name: |
Graeme Bell |
|
|
Title: |
Executive Vice President and |
|
|
|
Chief Financial Officer |
|
| ||
Date: January 11, 2016 |
|